EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory Disease

H B E Elzinga iD, J J Otten iD, M E Cornet, A B Rinia, R J L Van Der Lans, W J Fokkens iD, S Reitsma iD, PolyREG Consortium

Allergy · 2025

DOI: 10.1111/all.16579 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von H B E Elzinga und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Nasal Polyps, Antibodies, Monoclonal, Humanized, Sinusitis, Rhinitis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amsterdam UMC, AERO, GlaxoSmithKline foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with Non‐steroidal anti‐inflammatory drugs ( NSAID )‐Exacerbated Respiratory Disease (N‐ ERD ) can suffer from difficult‐to‐treat primary diffuse type 2 chronic rhinosinusitis with nasal polyps ( CRSwNP ). This study evaluates dupilumab effectiveness and dose tapering in CRSwNP patients with N‐ ERD compared to those without.

Methods

A real‐world prospective cohort with CRSwNP patients, with N‐ ERD or without ( CRSwNP ‐ NOS ; not otherwise specified), aged ≥ 18 treated with dupilumab 300 mg subcutaneously every 2 weeks. In case of clinical control, the interdose interval was prolonged every 6 months with steps of 2 weeks. (Clinical) data were collected at baseline, 24 weeks, and 2 years of treatment.

Results

Most baseline characteristics, including Nasal Polyp Score ( NPS ), Sino‐Nasal Outcome Test‐22 ( SNOT ‐22), and Sniffin′ sticks‐12 test ( SSIT ‐12) were comparable between groups (N‐ ERD n = 105, CRSwNP ‐ NOS n = 293). There was a higher prevalence (91.5% vs. 71.1%, p < 0.001) but comparable control of asthma in N‐ ERD patients (asthma control test [ ACT] : N‐ ERD 66.7% less controlled/uncontrolled vs. CRSwNP ‐ NOS 58.3%, p = 0.21). All outcomes improved significantly with dupilumab treatment at 24 weeks and remained improved after 2 years, without intergroup differences (median scores at 24 weeks for N‐ ERD patients vs. CRSwNP ‐ NOS , respectively: NPS : 2 vs. 1, p = 0.65; SNOT ‐22: 18 vs. 19, p = 0.27; SSIT ‐12: 7 vs. 8, p = 0.02; ACT : 21 vs. 22, p = 0.11). Dose tapering was possible in the majority of patients, with almost half at an 8–12 weeks interval in both groups after 2 years.

Conclusion

Dupilumab shows comparable effectiveness and taper feasibility between CRSwNP N‐ ERD patients and CRSwNP ‐ NOS patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal PolypsAntibodies, Monoclonal, HumanizedSinusitisRhinitisAnti-Inflammatory Agents, Non-SteroidalHumansMaleFemaleMiddle AgedChronic DiseaseTreatment OutcomeAdultAgedProspective StudiesRhinosinusitis

Stichwörter der Autor:innen

CRSwNPNSAID intoleranceNSAID‐exacerbated respiratory diseaseaspirine‐exacerbated respiratory diseasechronic rhinosinusitis with nasal polypsdupilumab

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Otorhinolaryngology, Alrijne Hospital, Leiden, the Netherlands.
  • Department of Otorhinolaryngology, Isala Hospital, Zwolle, the Netherlands.

ORCID-Profile: H B E Elzinga, J J Otten, W J Fokkens, S Reitsma

Förderung

  • Amsterdam UMC
  • AERO
  • GlaxoSmithKline foundation
  • Novartis
  • Sanofi
  • Amsterdam University Medical Centers

Zitieren

APA

Elzinga, H. B. E., Otten, J. J., Cornet, M. E., Rinia, A. B., Van Der Lans, R. J. L., Fokkens, W. J., Reitsma, S., & PolyREG Consortium (2025). Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory Disease. Allergy. https://doi.org/10.1111/all.16579

Vancouver

Elzinga HBE, Otten JJ, Cornet ME, Rinia AB, Van Der Lans RJL, Fokkens WJ, et al. Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory Disease. Allergy. 2025. doi:10.1111/all.16579

BibTeX
@article{Elzinga2025,
  author = {Elzinga, H B E and Otten, J J and Cornet, M E and Rinia, A B and Van Der Lans, R J L and Fokkens, W J and Reitsma, S and PolyREG Consortium, PolyREG Consortium},
  title = {Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory Disease},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16579}
}
Kostenlos starten →